AC Immune SA CEO Andrea Pfeifer noted in an interview with Scrip that more data are needed before the Swiss company and its partner Genentech, Inc. can determine next steps for semorinemab in Alzheimer’s disease. However, Pfeifer also pointed out that the anti-tau antibody achieved some firsts in the Phase II LAURIET clinical trial that may be worth examining in another study.
The partners announced on 31 August that semorinemab achieved statistical significance on the co-primary endpoint, showing a 43.6% reduction in...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)